Covaxin gets WHO approval for emergency use

Bharat Biotech’s Covaxin finally gets approval of emergency use of listing or EUL by the WHO. The decision will ease international travel and the export of the indigenous vaccine.

UNICEF, Pan-American Health Organization (PAHO), GAVI COVAX facility, will be able to keep Covaxin for distribution to countries worldwide, said Bharath Biotech.

With this decision, Indians who received the shot need not self-quarantine or face restrictions when traveling abroad. The UN health body tweeted, “WHO has granted emergency use listing (EUL) to #COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of Covid-19.” The approval of Covaxin was a long wait for India as it reduces and minimizes the quarantine and other issues with international travel.

The vaccine’s efficacy and other details have been studied by the Technical Advisory Group and as per their report, Covaxin has demonstrated 77.8 percent effectiveness against symptomatic Covid-19 and 65.2 percent protection against the new Delta variant.

Earlier, Covaxin has been cleared for use in all age groups (18+) over two doses four weeks apart. WHO said, no recommendation has been made for use on children, and available data for use on pregnant women is insufficient to assess safety or efficacy.

Read Also: Oman approves Covaxin for entering the country without quarantine

Many across the country congratulated Modi on this ‘win’ as the vaccine got WHO approval for its emergency use listing. Union Health Minister Mansukh Mandaviya also called it a ‘win for Atmanirbhar Bharat‘ and PM Modi’s goodwill and determination.
So far, the WHO has approved vaccines produced by American pharma giants Pfizer, Johnson & Johnson and Moderna, and China’s Sinopharm and Sinovac. Along with that, the Serum Institute of India’s Covishiled also got approval.